PFKFB3 and neoplasm: Gastric cancer cells resistant to trastuzumab exhibit increased glycolysis, and 6-phosphofructo-2-kinase (PFKFB3) was shown to activate glycolytic pathways, resulting in distinct changes in the tumor microenvironment [57,66].